NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/23/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,418.26 mln
Float273 mln
Earnings Date08/21/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.74
Likely manipulated
1-Year Forecast
20.73
Transformational upside
Relative Strength
90
/ 100
Top performer
Debt / Equity
1.12
Elevated leverage
Pre-Tax Margin
2%
Break-even
Business Description
Telix Pharmaceuticals is an Australian biopharmaceutical company founded in 2015 and headquartered in Melbourne, specializing in medicines that use targeted radiation to diagnose and treat cancer. The company has multiple products already on the market alongside a broad pipeline of treatments in development, targeting cancers including prostate, kidney, brain, bladder, and bone. Telix operates across Australia, North America, Europe, and other international markets, supported by partnerships with leading medical institutions.
